Mü llerian-inhibiting substance (MIS) is an essential factor for male sexual differentiation. In the present study, we examined whether the expression of MIS and several of its related transcription factors is altered in the ovaries of rats treated with the synthetic estrogen, E2 benzoate (EB; 10 g/0.02 ml), from postnatal day 1 (P1) to P5. The EB-treated rats had a significantly reduced number of layered follicles at P6 in comparison with the control rats that were treated with vehicle alone. The expression levels of both MIS mRNA and protein in the granulosa cells of small growing follicles in the ovary at P6 were higher in the EB-treated rats than in the controls. These 
I N MAMMALS, THE sexually indifferent gonad, which is
first histologically discernible early in gonadal development, differentiates into either a testis or an ovary. A number of factors involved in the molecular cascade for testicular differentiation in males, which is triggered by the transient expression of the Sry gene that is encoded on the Y chromosome, have been studied (1) . In contrast, female sexual differentiation was considered as an autonomous pathway in which no particular factors are required, and the molecular mechanisms that regulate ovarian differentiation, which occurs later than testicular differentiation, are poorly understood.
Mü llerian-inhibiting substance (MIS), also known as anti-Mü llerian hormone, is expressed by Sertoli cells of the fetal testis and is an essential factor for male sexual differentiation, based on its ability to cause regression of the Mü llerian duct, the anlagen of the uterus, oviducts, and the upper portion of the vagina, in the male (2) . In the female, MIS is produced by granulosa cells in postnatal ovaries (3) (4) (5) (6) . It is well known that MIS induces degeneration of granulosa cells, loss of oocytes, and appearance of testicular seminiferous tubulelike structures in the ovaries of freemartin, female fetuses that are exposed to excess MIS of a male twin by chorioallantoic anastomosis (7, 8) . Similar ovarian degeneration was observed soon after birth in metallothionein-human MIS (MT-hMIS) transgenic mice that chronically overexpress human MIS (9) . These reports suggest that an abnormally high MIS level inhibits ovarian differentiation. Recently, a role for MIS in the regulation of primordial follicle recruitment has been suggested by studies on the developing ovary of MIS-deficient mice (10) . Thus, it is probable that MIS plays an important role in controlling follicular development during postnatal ovarian development (11, 12) .
MIS gene expression appears to be regulated by several transcription factors. Steroidogenic factor 1 (SF-1, officially designated NR5A1), was originally found to be a transcriptional regulator of genes required for steroid production (13, 14), but it also activates MIS gene transcription in the fetal testis (15, 16) . In recent studies, it has been further proposed that transcriptional activation of the MIS gene by SF-1 is mediated through synergistic interactions with other transcription factors such as WT-1 (Wilms' tumor 1) (17), GATA-4 (a member of the GATA family of transcriptional regulators) (18, 19) , and Sox9 (SRY HMG box related gene 9) (20, 21), in fetal Sertoli cells. Because SF-1, WT-1, and GATA-4 are also expressed in granulosa cells of postnatal ovaries (22-25), these transcription factors may play equally important roles in regulating MIS gene expression in the ovary. Sox9 is normally not expressed in postnatal ovaries. However, it has recently been reported that female ␣␤ estrogen receptor knockout (␣␤ERKO) mice, in which both the ER-␣ and ER-␤ genes are disrupted, exhibited up-regulated expression of MIS and Sox9 in the sex-reversed adult ovary (26). This suggests that Sox9 expression in the ovary can be induced under certain abnormal circumstances.
Neonatal female rats or mice exposed to a synthetic estrogen such as E2 benzoate (EB) or diethylstilbestrol, exhibit morphological and functional abnormalities in the adult Abbreviations: EB, E2 benzoate; ␣␤ERKO, ␣␤ estrogen receptor knockout; GATA-4, a member of the GATA family of transcriptional regulators; HE, hematoxylin and eosin; MIS, Mü llerian-inhibiting substance; MT-hMIS, metallothionein-human MIS; P, postnatal day 1; SF-1, steroidogenic factor 1; SSC, standard saline citrate; Sox9, SRY HMG box related gene 9; WT-1, Wilms' tumor 1. ovary (27, 28). We previously reported that the expression levels of genes required for steroidogenesis were greatly reduced in the developing ovary of neonatally EB-exposed rats, suggesting that EB exposure inhibits theca/interstitial cell differentiation (29). The present study focuses on the molecular events accompanying the inhibition of follicular development; in this study, the expression of MIS and several of its related transcription factors in granulosa cells of the ovary after neonatal exposure to EB is examined. Our results suggested that the inhibitory effect of EB on early follicular growth is due to altered expression of MIS and SF-1, providing insights into a possible mechanism by which EB causes a delay in ovarian development and also a molecular mechanism that regulates postnatal ovarian development.
Materials and Methods

Animal treatment and tissue preparation
Sprague Dawley rats were maintained under standard conditions, and a total of 44 female rats that were born in our facility were used. Newborn females were given daily sc injections of either 10 g EB (Sigma, St. Louis, MO) dissolved in 0.02 ml olive oil (n ϭ 26) or an equal volume of olive oil alone (n ϭ 18) for 5 consecutive days starting on the day of birth (P1). On P6, P14, or P21, control (olive oil-treated) and EB-treated rats (n ϭ 5/group/ age, or more depending on the age of the animal) were deeply anesthetized and perfused transcardially with ice-cold 4% paraformaldehyde in 0.1 m PBS. The ovaries were removed, placed into the same fixative solution overnight at 4 C, embedded in paraffin, and serially sectioned at 6-m thickness, and the sections were mounted on silane-coated slides. The tissue sections were processed for histological examination, in situ hybridization, or immunohistochemistry as described below. All animals were handled in accordance with the principles and procedures outlined in the NIH Guide for the Care and Use of Laboratory Animals.
Antibodies
For immunohistochemical analyses, the following antibodies were used. The goat polyclonal MIS antibody (catalog no. sc-6886; Santa Cruz Biotechnology, Inc., Santa Cruz, CA) is raised against a carboxy terminal peptide of the precursor form of human MIS. The rabbit polyclonal WT-1 antibody (catalog no. sc-192; Santa Cruz Biotechnology, Inc.) is raised against a carboxy terminal peptide of human WT-1. The goat GATA-4 antibody (catalog no. sc-1237; Santa Cruz Biotechnology, Inc.) is raised against a carboxy terminal peptide of mouse GATA-4. The two rabbit polyclonal antibodies to ER-␤, antibody no. PC168 (Oncogene Research Products, Boston, MA) and antibody no. PAI-310 (Affinity BioReagents, Inc., Golden, CO), are both raised against a synthetic peptide corresponding to the carboxy terminal amino acid residues 467-485 of the rat ER-␤ protein. For detection of SF-1, the same antibody generated in a previous study (29) was used.
In situ hybridization
Sense and antisense riboprobes for MIS (15), SF-1 (13), Sox9 (30), and ER-␤ (31) were generated with T7, T3, and SP6 RNA polymerases and a SureSite T7 RNA Probe Kit (Novagen Inc., Madison, WI). In situ hybridization was performed using a SureSite Hybridization Reagents Kit (Novagen). In brief, sections were dewaxed in xylene, rehydrated in graded ethanols, treated with 0.2 n HCl, digested with proteinase K (1 g/ml) for 5 min, and acetylated with 0.25% acetic anhydride. After prehybridization, the sections were hybridized with the respective probe at 50 C overnight. Then, the sections were rinsed in 2ϫ SSC (standard saline citrate), treated with RNase A (20 g/ml) for 30 min, washed once in 2ϫ SSC and twice in 1ϫ SSC, and air-dried. Sections were dipped in Kodak NTB-2 nuclear tracking emulsion (Eastman Kodak Co., Rochester, NY) and exposed at 4 C for 1 or 2 wk. The sections were developed in Kodak D19, fixed in Kodak fixer, and counterstained with methyl green (Sigma). To ensure that in situ hybridization procedures were carried out under the same conditions, sections from the control and treated animals were mounted on the same slides. In situ hybridization analysis was performed at least twice per tissue sample using each probe, and at least two different samples were used per data point. Control studies were performed using the sense probe and no signals higher than the background level were detected.
Quantification of MIS mRNA levels
To quantify the MIS mRNA level, sections were observed under brightfield illumination using an Olympus Corp. AX80T microscope and an objective with a ϫ60 magnification. The silver grains in 10 random fields in each follicle were counted. Background counts were determined by counting silver grains in 10 random fields in regions of the same sections that were outside the ovary, and the average of the grain counts in these regions was deducted from the grain count in the follicle. The silver grains were counted at least three times from three different litters for each treatment group, and the group mean Ϯ sem was calculated.
Histology and immunohistochemistry
Sections were dewaxed in xylene and rehydrated in graded ethanols. For histological examination, sections were stained with hematoxylin and eosin (HE). For immunohistochemical analyses, sections that were to be incubated with the antibodies against WT-1, GATA-4, ER-␤, or SF-1 were subjected to antigen retrieval by microwaving in 10 mm citrate buffer (pH 6.0) on full power for 5 min, and then cooled to room temperature. After washing in PBS, endogenous peroxidase activity was blocked by immersing the sections in 3% (vol/vol) hydrogen peroxidase in PBS for 5 min. The sections were washed again in PBS and incubated in a blocking solution containing 5% BSA in PBS at room temperature for 30 min. The sections were subsequently incubated with the primary antibody diluted appropriately with the blocking solution overnight at 4 C. The primary antibodies included rabbit anti-SF-1 (1:10000 dilution), goat anti-MIS (1:5000 dilution), rabbit anti-WT-1 (1:50000 dilution), goat anti-GATA-4 (1:5000 dilution), and rabbit anti-ER-␤ (1:200 or 1:500 dilution). Biotinylated secondary antibodies (Vector Laboratories, Inc., Burlingame, CA) were detected using a Vectastain ABC Elite kit (Vector Laboratories, Inc.) and a VectaDAB or NovaRED substrate kit (Vector Laboratories, Inc.). Negative controls were prepared by substitution of the primary antibody with normal rabbit or goat IgG and by omission of the primary and/or the secondary antibody. No staining above the background was detected. The specificity of the MIS antibody was further ascertained by incubating adjacent sections with the antibody preabsorbed with the peptide against which the antibody had been raised. Preabsorption of the MIS antibody with the immunizing peptide abolished immunostaining for MIS in both the control and EB-treated ovaries. To minimize the variation in staining, sections from the control and treated animals of the same age were mounted on the same slide, FIG. 1. Quantitative evaluation of follicular development in control and EB-treated ovaries. Female rat neonates were given daily sc injections of EB or olive oil on P1-P5. The entire ovarian area in 6-m-thick paraffin sections stained with HE was observed under a light microscope, and the number of secondary follicles in every tenth section of the serial sections were counted in oil-(Oil) and EB-treated (EB) ovaries at P6. The sum of the number of secondary follicles in each ovary was calculated. Each column represents the mean Ϯ SEM of five (Oil) or six (EB) ovaries per group (*, P Ͻ 0.05 vs. control).
and immunohistochemical procedures for sections from groups of different ages were carried out in parallel.
Quantitative evaluation of follicular development
Quantitative evaluation of follicular development in the ovaries of the control and EB-treated P6 rats was performed. The entire ovarian area in 6-m-thick paraffin sections stained with HE was observed under an Olympus Corp. (Hamburg, Germany) AX80T microscope with an objective with ϫ40 magnification. Secondary follicles were counted in every 10th section of serial sections of an ovary and are indicated as the sum. Each column in Fig. 1 represents the mean Ϯ sem for five (Oil) or six (EB) ovaries per group.
FIG. 2. Effect of neonatal EB treat-
ment on the expression of MIS mRNA in the developing rat ovary. The expression of MIS mRNA was analyzed using in situ hybridization. A-D, Bright-field and dark-field images of the central section of representative ovaries from oil-(Oil) and EB-treated (EB) animals at P6. Note that the in situ hybridization signals for MIS mRNA in size-matched secondary follicles in the EB-treated ovary (arrowheads) are more intense than those in the control ovary (arrows). E and F, Dark-field images of the central section of representative ovaries from oil-and EB-treated animals at P14. Scale bar, 100 m.
Quantification of SF-1 protein in granulosa cells
Sections immunostained for SF-1 were observed under an Olympus Corp. AX80T microscope with an objective with ϫ40 magnification. Immunoreactivity for SF-1 was observed in some of the granulosa cells of primary and secondary follicles with variable intensity, in both the control and EB-treated ovaries at P6. To examine whether neonatal treatment with EB alters SF-1 expression in granulosa cells, the intensity of SF-1-immunoreactivity in granulosa cells was evaluated by scoring each cell as ϩϩϩ (intense; i.e. equivalent to the immunoreactivity in theca/interstitial cells of the control ovary), ϩϩ (moderate), ϩ (weak), or Ϫ (undetectable). The number of intensely-SF-1-immunoreactive granulosa cells scored as ϩϩ or ϩϩϩ were counted and the results were expressed as the percentage of intensely-SF-1-immunoreactive granulosa cells to the total number of granulosa cells. Sections from five different animals for each treatment group and at least 10 follicles from each animal were examined, and the group mean Ϯ sem was calculated.
Statistical analyses
Data on the number of multiple-layer follicles, the MIS mRNA level, and the expression level of SF-1 protein were analyzed using ANOVA (Single Factor; Microsoft Excel 97 SR-2, Microsoft Corp., Redmond, WA), to evaluate the significance of differences between the control and EBtreated rats. P Ͻ 0.05 was considered to be significantly different.
Results
Effect of EB exposure on follicular development
In our previous study, histological examination demonstrated that secondary follicles were less abundant in the EB-treated ovary than in the control ovary at P6 (29). In the present study, we quantitatively analyzed the histological results, and found that the number of secondary follicles in the EB-treated ovaries was significantly lower than that in the control ovaries at P6 (Fig. 1) . These results indicate that EB inhibits the formation of layered follicles.
Expression of MIS mRNA and protein in EB-treated ovaries
The results shown in Fig. 1 indicate that EB may affect the expression of factors required for follicular development. Therefore, we examined the expression of MIS and several of its transcription factors in EB-treated ovaries using in situ hybridization and/or immunohistochemistry.
At P6, in situ hybridization signals for MIS mRNA were not detected in primordial follicles, but intense signals were detected in the primary and secondary follicles in both the control and EB-treated ovaries (Fig. 2, A and B) . The signal intensity was apparently higher in the EB-treated ovaries than in the control ovaries when secondary follicles of similar sizes were compared (Fig. 2, A-D) . At P14 and thereafter, the signals for MIS mRNA were intense in smaller follicles at the stages ranging from primary to small antral follicles but were less intense or nearly negative in larger follicles such as the medium and large antral follicles in both the EB-treated and control ovaries (Fig. 2, E and F, and data not shown). The signal intensity was still higher in the EB-treated ovaries than in the control ovaries at P14 (Fig. 2, E and F) , but the signal intensity of MIS mRNA in the two treatment groups were similar at P21 (data not shown). Quantitative analysis revealed that the number of silver grains of MIS mRNA per secondary follicle in the EB-treated ovaries was approximately 2 times higher than that in the control ovaries (Fig. 3) .
The distribution of MIS protein was examined by immunohistochemistry. At P6, cytoplasmic immunoreactivity for MIS was not detected in the squamous pregranulosa cells of primordial follicles but was detected in the cuboidal granulosa cells of primary and secondary follicles in both the control and EB-treated ovaries (Fig. 4, A-D) . At later stages of development, the level of MIS protein decreased in larger follicles such as medium and large antral follicles (Fig. 4 , E-H). The staining intensity was apparently higher in the EB-treated ovaries than in the control ovaries at P6 (Fig. 4 , A-D) and P14 (Fig. 4, E and F) , but became similar at P21 (Fig.  4, G and H) .
Thus, the levels of both MIS mRNA and protein in granulosa cells of small growing follicles were higher in the EB-treated ovaries than in the control ovaries for approximately 2 wk postnatally.
Expression of SF-1 in granulosa cells of EB-treated ovaries
SF-1 is expressed in both theca/interstitial cells and granulosa cells in postnatal ovaries. To study whether neonatal EB treatment induces any change in the expression level of SF-1 in granulosa cells, the cellular level of SF-1 was examined by immunohistochemistry and the levels were quantitatively analyzed. The immunohistochemical results were consistent with those of our previous study, demonstrating that nuclear immunoreactivity for SF-1 was observed in some granulosa cells with variable intensity in both the control and EB-treated ovaries throughout the postnatal development (Ref. 29 and data not shown). The percentage of intensely SF-1-immunoreactive granulosa cells in the primary and secondary follicles was significantly higher in the EB-treated ovaries than in the control ovaries at P6 (Fig. 5) . At P14 and thereafter, there were no significant differences in either the localization or the staining intensity of SF-1 in granulosa cells between the two treatment groups (Ref. 29 and data not shown).
Expression of other transcription factors in EB-treated ovaries
The expression of WT-1 and GATA-4 was examined by immunohistochemistry. At P6, WT-1 was detected in gran- FIG. 3 . Quantification of the results obtained by in situ hybridization for MIS. To quantify the MIS mRNA level in granulosa cells, sections were observed under bright-field illumination, and the silver grains in the secondary follicles in the P6 ovary were counted as described in Materials and Methods. The results were analyzed using ANOVA and the data are presented as the mean Ϯ SEM for 10 (Oil) or 8 (EB) follicles obtained from at least three animals per group (*, P Ͻ 0.05 vs. control). The number of silver grains in the secondary follicles of the EB-treated (EB) ovaries was significantly higher than that in the control (Oil) ovaries.
ulosa cells of growing follicles and surface epithelial cells (Fig. 6, A-D) , and GATA-4 was detected in granulosa cells, theca/interstitial cells and surface epithelial cells (Fig. 6 , E-H) of both the control and EB-treated ovaries. There was no apparent difference in the expression profile of either of these two factors between the control and EB-treated ovaries at all time points examined (Fig. 6 , and data not shown). Sox9 expression was examined by in situ hybridization, but no signals for Sox9 mRNA were detected in any of the control and EB-treated ovaries at any postnatal day examined (data not shown).
The biological functions of estrogens are mediated via ERs. Because ⌭R-␤ is highly expressed in granulosa cells and ER-␣ expression is limited to theca/interstitial cells during early postnatal development (29, 32, 33), ⌭R-␤ seems to mediate the action of estrogen in granulosa cells. To determine whether estrogens affect ER-␤ expression, we examined the expression of ER-␤ mRNA and protein in EB-treated ovaries by in situ hybridization and immunohistochemistry, respectively. Faint signals of ER-␤ mRNA were distributed diffusely over the inner ovarian part, where secondary follicles are located, in both the control and EB-treated ovaries at P6 (Fig. 7, A and B) . The signals became intense and were localized in growing follicles at P14 and P21 (Fig. 7, C and D, and data not shown). There was no apparent difference in the signal intensity of ER-␤ mRNA between the control and EB-treated ovaries at P6 (Fig. 7, A and B) ; however, at P14, the signals in small secondary follicles of similar size were slightly more intense in the EB-treated ovaries than in the control ovaries (Fig. 7, C and D) . The immunohistochemical results shown in Fig. 7 are based on studies using antibody no. PC168, but comparable results were obtained using an- tibody no. PAI-310. ER-␤ protein was not found in any of the EB-treated and control ovaries at P6 (data not shown). In both the control and EB-treated ovaries at P14 and P21, immunoreactivity for ER-␤ was observed in some, but not all, granulosa cells of the growing follicles and was localized in the cellular nucleus (Fig. 7, E-H) . Some cytoplasmic staining for ER-␤ was detected in interstitial cells of the control ovaries but not in those of the EB-treated ovaries (Fig. 7, E and F) .
Discussion
Quantitative histological evaluation revealed a significant reduction in the number of secondary follicles in the EBtreated ovaries compared with that in the control ovaries as early as P6. These findings confirm our previous histological observation (29), and indicate that estrogen inhibits the onset of follicular stratification in the developing ovary.
The temporal and spatial expression patterns of MIS mRNA and protein during postnatal ovarian development are consistent with earlier findings (3-6). The detection of very strong MIS expression in the primary and secondary follicles, where granulosa cells are actively proliferating, supports the idea that MIS plays a role in controlling early follicular growth (10) .
The present results showed that the levels of both MIS mRNA and protein in granulosa cells were elevated in small growing follicles in the EB-treated ovaries for approximately 2 wk after birth. These results seem to be inconsistent with our previous results from RT-PCR in which there was no apparent difference in the total amount of MIS mRNA between the control and EB-treated ovaries at any developmental stage examined (29). This discrepancy must be due to the reduced number of follicles strongly expressing MIS in the EB-treated ovaries. The present results also seem to contradict the results reported by Baarends et al. (6) in which MIS expression was reduced in preantral and small antral follicles in the adult rat ovary after EB treatment. In adult animals, the effect of estrogens is thought to be secondary to the pituitary gonadotropins, with MIS expression hormonally regulated by a feedback system on the hypothalamic-pituitary-gonadal axis. However, ovaries are thought to be unresponsive to pituitary gonadotropins before 1 wk of age (34, 35) , and therefore the effect of EB on the regulation of MIS expression in the early developing ovary is probably a direct action.
An abnormally high MIS level causes ovarian degeneration in freemartin twin females (7, 8) , and in MT-hMIS transgenic female mice overexpressing human MIS during fetal and early postnatal development (9, 36) . Furthermore, MThMIS transgenic female mice that have a targeted mutation in the MIS type II receptor (MISRII) gene, develop normal ovaries, suggesting that the ovarian degeneration caused by excess MIS in MT-hMIS transgenic mice is specifically mediated by the MISRII normally expressed in granulosa cells (37) . Therefore, the inhibition of follicular development observed in the EB-treated ovaries may be due to the effect of abnormally high MIS levels mediated via MISRII in granulosa cells.
In males, the differentiation of Leydig cell precursors and the expression of steroidogenic enzyme mRNA were blocked in MIS transgenic male mice and in MIS-treated purified Leydig cells, suggesting a paracrine effect of MIS, which is expressed by Sertoli cells and binds to Leydig cells expressing MISRII (38 -41) . In a previous in situ hybridization study (6) , signals for MISRII mRNA were distributed evenly over the entire ovary during the early stages of postnatal development, indicating the possible expression of this gene in cells in the theca/interstitial region. Therefore, the reduction of the extent of steroidogenesis and the inhibition of theca/ interstitial cell differentiation in EB-treated ovaries observed in our previous study (29) may be caused by excess MIS produced by granulosa cells, in a paracrine-mediated manner, acting via MISRII on theca/interstitial cells.
In contrast to the marked reduction in the number of SF-1-expressing cells among theca/interstitial cells in the EB-treated ovary, which was demonstrated in our previous study (29), our present results showed a significant increase in SF-1 expression in granulosa cells of EB-treated ovaries. These results also seem to be inconsistent with the reduction of the total expression level of SF-1 shown by RT-PCR analysis in the study of Morais da Silva et al. (30) . Because the number of SF-1-expressing cells is larger and the expression level is higher in theca/interstitial cells than in granulosa cells (42, 43) , the total expression level of SF-1 mainly reflects the expression level in theca/interstitial cells. Thus, it was revealed that estrogen has a different effect on SF-1 expres- sion in granulosa cells and in theca/interstitial cells within an ovary. Although the regulation of MIS expression by SF-1 has not been proven in ovarian granulosa cells, the concomitant increase in the levels of these two factors indicates a functional correlation of these two factors in the developing ovary.
The colocalization of MIS and ⌭R-␤ in granulosa cells of growing follicles in the developing ovary and the presence of an estrogen-responsive halfsite element in the promoter region of the MIS gene (44) suggest that MIS acts on granulosa cells via ER-␤. In the present study, increased levels of both ⌭R-␤ mRNA and protein in secondary follicles of EBtreated ovaries were observed at P14 but not at P6. Because the level of ⌭R-␤ expression is very low in neonatal rats (45) , it might be difficult to detect slight changes by in situ hybridization or immunohistochemistry. Therefore, the possibility that ⌭R-␤ directly or indirectly mediates the inhibitory effect of EB on follicular formation cannot be ruled out.
At present, the expression site of ⌭R-␤ in the ovary is controversial (46) . Although ⌭R-␤ mRNA is strongly expressed in granulosa cells, several groups have reported that it is also expressed in theca cells by in situ hybridization (47) (48) (49) . In our study, in situ hybridization signals for ⌭R-␤ were localized in granulosa cells and no signals were detected in the theca/interstitial region. We observed some cytoplasmic staining for ER-␤ in interstitial cells of the control but not in those of the EB-treated ovaries by immunohistochemistry. Similar cytoplasmic staining of ⌭R-␤ was also reported by Sar and Welsch (32) using antibody no. PAI-310. In that report, the cytoplasmic staining was not completely blocked in sections that were incubated with preabsorbed ER-␤. In contrast, Fitzpatrick et al. did not detect cytoplasmic staining in interstitial cells using either antibody no. PC168 or antibody no. PAI-310 (33) . These different results may be related to the technical differences such as tissue fixation, tissue preparation (frozen or paraffin sections), and permeabilization treatment (proteases, detergent, and microwaving). In the present study, no cytoplasmic staining was observed in the negative control sections in which the primary antibody was omitted. Because absorption is a more stringent indicator of specificity, we cannot yet evaluate the specificity quantitatively.
It has been suggested that ER-␣ and ER-␤ are functionally redundant in ovarian folliculogenesis and that ER-␤ plays an important role in mediating the action of estrogen in stimulating granulosa cell proliferation during follicular growth (46) . Recently, the importance of both ERs has been suggested in ␣␤ERKO female mice (26, 50). The ovaries of adult ␣␤ERKO females showed several features of sex-reversal, such as degeneration of granulosa cells, loss of germ cells, appearance of Sertoli-like cells, and elevated mRNA levels of marker genes for Sertoli cells (MIS, sulfated glycoprotein-2, and Sox9). These results suggest that the sex-reversal is due to aberrant expression of factors for both oocyte survival (such as GATA-4) and Sertoli cell differentiation (such as MIS and Sox9) caused by the lack of ERs (26). However, immunoreactivity for MIS was not increased in the Sertoli-like cells of the ␣␤ERKO ovaries, indicating that the appearance of Sertoli-like cells is independent of increased MIS expression but is correlated with oocyte loss (50) . In the EB-treated ovaries, elevated MIS mRNA levels were detected only temporarily during the early neonatal period, and we did not observe any sign of sex-reversal such as appearance of Sertoli-like cells, loss of oocytes or Sox9 expression. In spite of these differences, altered expression of both ER-␣ and ER-␤ was observed in the EB-treated ovaries, which was shown in the previous (29) and present studies, respectively. These findings indicate that both ERs are important for postnatal ovarian differentiation, and the presence of a functional correlation between MIS and ERs.
There were no differences in the expression profiles of WT-1 or GATA-4 between the control and EB-treated ovaries by immunohistochemistry. Because these factors were suggested to be involved in follicular development (22, 23), it is possible that subtle changes in the expression levels of these factors that were not detected by this method might have occurred in the EB-treated ovaries.
To our knowledge, the present study is the first to show that neonatal estrogen treatment increases the expression of MIS and inhibits follicular growth during early postnatal development of the rat ovary. These results indicate that exogenous estrogen inhibits ovarian follicular growth by altering the expression of MIS and that SF-1 and/or ER-␤ may be involved in the estrogen-induced up-regulation of MIS expression in the developing ovary.
